Order Article Reprints

Vernieri C, Prisciandaro M, Nichetti F, Lobefaro R, Peverelli G, Ligorio F, Zattarin E, Cona MS, Sepe P, Corti F, et al. Oral Capecitabine-Vinorelbine Is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer. Cancers. 2020; 12(3):617. https://doi.org/10.3390/cancers12030617

Vernieri, Claudio, Michele Prisciandaro, Federico Nichetti, Riccardo Lobefaro, Giorgia Peverelli, Francesca Ligorio, Emma Zattarin, Maria Silvia Cona, Pierangela Sepe, Francesca Corti, and et al. 2020. "Oral Capecitabine-Vinorelbine Is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer" Cancers 12, no. 3: 617. https://doi.org/10.3390/cancers12030617

Vernieri, C., Prisciandaro, M., Nichetti, F., Lobefaro, R., Peverelli, G., Ligorio, F., Zattarin, E., Cona, M. S., Sepe, P., Corti, F., Manglaviti, S., Brambilla, M., Re, B., Belfiore, A., Pruneri, G., Celio, L., Mariani, G., Bianchi, G. V., Rivoltini, L., ... de Braud, F. (2020). Oral Capecitabine-Vinorelbine Is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer. Cancers, 12(3), 617. https://doi.org/10.3390/cancers12030617